Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe’s Oral Edaravone Filed in Japan for ALS
March 15, 2022
- ViiV Submits Long-Acting Cabotegravir Injectable for HIV in Japan
March 14, 2022
- Nubeqa Filed for Metastatic Prostate Cancer in Japan: Bayer
March 14, 2022
- Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
- Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
- Shionogi, XNef, ATR Join Hands on R&D for Diagnosis/Stratified Markers of Neuropsychiatric Disorders
March 14, 2022
- Sumitomo Dainippon Invests an Additional 200 Million Yen into Aikomi
March 14, 2022
- Toho Gets 20% Stake in Ayumi’s Holdings Firm, Eyes RA Biosimilar Market
March 11, 2022
- Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
March 11, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Toa Eiyo Kickstarts Japan PIIb/III for Sakigake Designated TGCV Med
March 11, 2022
- Japan Drug Makers Moving to Support War-Hit Ukraine
March 10, 2022
- Opdivo Tops Japan Sales Ranking in February: Encise
March 10, 2022
- Astellas to Submit Improvement Plans for Gene Therapy Trial by September over Patient Deaths
March 10, 2022
- Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
- Rakuten Medical’s Photoimmunotherapy Platform Renamed Alluminox
March 9, 2022
- Nobelpharma, Toyo Ink Tie Up on Biologics Development, Overseas Expansion
March 9, 2022
- Nippon Chemiphar Gets Japan Sales Rights to Another Delta-Fly Cancer Med
March 9, 2022
- Astellas’s Hot Flash Drug Fezolinetant Delivers Positive PIII Data
March 8, 2022
- SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
March 8, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…